Athira Pharma, Inc. — Director's Dealing 2022

Oct 18, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2022-10-13

Reporting Person: MOEBIUS HANS (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-10-13	Common Stock	M	7881	$1.35	Acquired	60836	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-10-13	Stock Option (Right to Buy)	$1.35	M	7881	Disposed	2029-08-14	Common Stock (7881)	Direct

Footnotes

F1: One-fourth of the shares subject to the option vested on June 1, 2020 and one-fourth of the shares subject to the option vest on each year thereafter.